Full Federal Court strikes down patent for clopidogrel

The Full Federal Court has confirmed that Sanofi-Aventis’ patent for the drug clopidogrel (brand name Plavix) is invalid and should be revoked.  Subject to the question of whether Sanofi will seek a stay pending an application for leave to appeal to the High Court, the decision clears the way for Apotex and other companies to launch their own brands of clopidogrel, a drug designed to prevent platelet aggregation and blood clots, to compete directly with Sanofi.

Our analysis of the Full Court’s decision can be found here.

 

 

Leave a Reply

Your email address will not be published. Required fields are marked *

7 − 7 =